| Literature DB >> 35329645 |
Valeria Cannillo1, Roberta Salvatori2, Stefania Bergamini3, Devis Bellucci1, Carlo Bertoldi3.
Abstract
The present review deals with bioactive glasses (BGs), a class of biomaterials renowned for their osteoinductive and osteoconductive capabilities, and thus widely used in tissue engineering, i.e., for the repair and replacement of damaged or missing bone. In particular, the paper deals with applications in periodontal regeneration, with a special focus on in vitro, in vivo and clinical studies. The study reviewed eligible publications, identified on the basis of inclusion/exclusion criteria, over a ranged time of fifteen years (from 1 January 2006 to 31 March 2021). While there are many papers dealing with in vitro tests, only a few have reported in vivo (in animal) research, or even clinical trials. Regardless, BGs seem to be an adequate choice as grafts in periodontal regeneration.Entities:
Keywords: animal model; bioactive glasses; bone regeneration; clinical trials; coatings; in vitro tests; in vivo tests; periodontal regeneration; scaffolds
Year: 2022 PMID: 35329645 PMCID: PMC8954447 DOI: 10.3390/ma15062194
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1BGs use as regenerative surgical treatment in dentistry.
Figure 2Schematic illustration of the BGs effect on periodontal cells.
Figure 3Articles distribution in clinical/in vitro/in vivo studies in periodontal regeneration with BGs, from 2006 to 2021.
Figure 4Different types of BGs used in clinical studies in periodontal patients from 2006 to 2021.
Figure 5Flow diagram of the included articles.
Summary of in vitro studies.
| References | Materials | Type of Cells and Tests |
|---|---|---|
| Balamurugan et al. [ | Sol-gel BG containing silver | |
| Varanasi et al. [ | (i) commercial 45S5 and (ii) an experimental BG | Human periodontal ligament fibroblasts (hPDLF) |
| Casarrubios et al. [ | mesoporous BG nanospheres | MC3T3-E1 pre-osteoblasts |
| Bai et al. [ | Boron-containing mesoporous bioactive glass nanospheres (with average size of 60 nm) | Human periodontal ligament cells (hPDLCs) |
| Wu et al. [ | Strontium containing mesoporous BG scaffolds | Human periodontal ligament cells (hPDLCs) |
| Jia et al. [ | Porous mesoporous BG scaffolds, containing strontium (Sr 5 mol.) | Periodontal ligament stem cells (PDLCs) |
| Carvalho et al. [ | Bioactive glass nanoparticles (BGNP) | Osteoblasts rat calvaria |
| Sowmya et al. [ | Nanocomposite scaffold based on chitin hydrogel and bioactive glass ceramic particles (nBGC) | Human osteosarcom a cell line (MG63) |
| Sowmya et al. [ | Three-layer nanocomposite scaffold consisting of: (i) chitin—PLGA/nanobioactive glass ceramic (nBGC)/cementum protein 1, (ii) chitin—PLGA/fibroblasts growth factor 2 and (iii) chitin—PLGA/nBGC/platelet-rich plasma-derived growth factors | Human dental follicle stem cells (hDFCs) |
| Uskoković et al. [ | Nanocomposites: niobium- and zinc-doped bioglass-ceramic particles and chitosan | Odontoblast-like MDPC-23 cells Cell viability (CellTiter-Blue assay) |
| Srinivasan et al. [ | Composite scaffold: alginate and nanobioactive glass ceramic particles (nBGC, CaO–SiO2–P2O5 ternary system) | Human periodontal ligament fibroblast (hPDLF) |
| Esfahanizadeh et al. [ | BG doped with zinc compared to 45S5 | Antibiofilm activity |
| Caridade et al. [ | Composite membranes: poly ( | Saos-2 cells |
| Moonesi et al. [ | Bilayer membranes (of cellulose acetate) containing BG nanoparticles modified with boron | Human dental pulp stem cells (hDPSCs) |
| Mota et al. [ | Membrane: chitosan with bioactive glass nanoparticles (BG-NP) | Human periodontal ligament cells (hPDL) and human bone marrow stromal cells (hBMSC). Cell viability (Alamar Blue test) |
| Ruiz-Clavijo et al. [ | Binary glasses (CaO-SiO2) | Human osteosarcoma cell line (MG63) |
| Shah et al. [ | Three-layered functionally graded membranes, with various concentrations of BG nanoparticles | Murine pre-osteoblasts cell line (MC3T3-E1) |
| Sunandhakumari et al. [ | Membranes: polycaprolactone (PCL) and BG particles | Murine fibroblast cell line (L-929 Cell viability (XTT assay)) |
| Beketova et al. [ | BG/ceramic dental composite | Periodontal ligament fibroblasts (PDLFs) |
| Granel et al. [ | BG and PCL | Rat primary osteoblastic (RPO) cells |
| Meneses et al. [ | Gutta-percha/niobium phosphate glass | Human periodontal ligament fibroblasts (hPDLF) |
| Theocharidou et al. [ | BG/ceramic composite scaffolds | Human periodontal ligament fibroblasts (hPDLF) |
| Carvalho et al. [ | BG by sol-gel | Cementoblasts (from the molars extracted from Wistar male rats) |
| Wen et al. [ | BG based on the xSiO2-CaO-P2O5 system | Human periodontal ligament cells (hPDLCs) |
Summary of in vivo studies (in animal).
| References | Materials | Animal and |
|---|---|---|
| Carvalho et al. [ | (i) BG (Perioglas®, 90–710 µm); (ii) plasma rich in platelets (PRP); (iii) BG and PRP; (iv) control | 9 mongrel dogs |
| Felipe et al. [ | (i) membrane and Perioglas® (particles size 90 to 710 microns); (ii) membrane and BioGran (particles size 300 to 355 microns); (iii) membrane alone; (iv) negative control | 6 dogs |
| Lee et al. [ | (i) an amorphous calcium phosphate glass cement with collagen membrane (CM), (ii) biphasic calcium phosphate with CM, (iii) CM alone and (iv) surgical flap operation only (control group, not grafted) | 5 beagle dogs |
| Sowmya et al. [ | Nanocomposite scaffold (chitin hydrogel and bioactive glass ceramic particles—nBGC) | 12 rabbits |
| Zhang et al. [ | (i) unfilled defects as control, (i) a BG scaffold (BG: CaO-P2O5-SiO2) and (iii) a scaffold made of BG also containing strontium | 15 osteoporotic rats |
| Granel et al. [ | Bioactive glass and polycaprolactone (PCL) | 14 rats (calvaria) |
| Shah et al. [ | Three-layered functionally graded membranes: lower layer with 50% wt. bioactive glass nanoparticles (BG-NP), middle layer 25% wt. BG-NP and upper layer no BG-NPs | 8 wistar rats |
Summary of clinical studies.
| References | Materials | Number of Patients and Follow-Up |
|---|---|---|
| Humagain et al. [ | PerioGlas® | 16 patients |
| Keles et al. [ | PerioGlas® | 15 patients |
| Demir et al. [ | Unigraft® (200–420 μm) | 29 patients |
| Cetinkaya et al. [ | PerioGlas® | 11 patients |
| Kaur et al. [ | PerioGlas® | 10 patients |
| Katuri et al. [ | PerioGlas®, Grafton® | 10 patients |
| Sculean et al. [ | Enamel matrix protein derivative (EMD) and bioactive glass | 10 patients |
| Kumar et al. [ | Bonelike® (glass reinforced HA with α and β forms of tricalcium-phosphate) | 10 patients |
| Satyanarayana et al. [ | PerioGlas® | 12 patients |
| Subbaiah and Thomas [ | PerioGlas® | 8 patients |
| Mistry et al. [ | PerioGlas® | 22 patients |
| Lysienko and Borysenko [ | BG graft. BG doped with 1% silver and 0.5% copper | 47 patients |
| Slezák et al. [ | NovaBone® | 10 patients |
| Grover et al. [ | NovaBone® | 12 patients |
| Asmita et al. [ | NovaBone Dental Putty® graft or BG (PerioGlas®) | 28 patients |
| Biswas et al. [ | NovaBone Dental putty® | 15 patients |
| Naqvi et al. [ | NovaBone® | 20 patients |
| Saravanan et al. [ | BG putty | 20 patients |
| Koduru et al. [ | Nanocrystalline hydroxyapatite (Nc-HA) (Sybograf ™) | 20 patients |
| Bansal et al. [ | NovaBone® | 10 patients |